Reneo Pharmaceuticals shares plunged after the company said a study of mavodelpar in adults with primary mitochondrial myopathies failed to meet its primary or secondary efficacy endpoints. Piper.
Reneo Pharmaceuticals Inc. is halting development of its only asset, mavodelpar, after a phase IIb study missed its primary and secondary efficacy endpoints. The selective peroxisome proliferator-activated receptor (PPAR)-delta agonist was being developed to treat to rare genetic mitochondrial diseases.
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Free Report)‘s stock had its “hold” rating reissued by Jefferies Financial Group in a research report issued on Friday, Marketbeat Ratings reports. Other equities analysts have also issued research reports about the stock. LADENBURG THALM/SH SH lowered shares of Reneo Pharmaceuticals from a “buy” rating to a “neutral” rating in […]
Reneo Pharmaceuticals (RPHM) Reports Results from Pivotal STRIDE Study of Mavodelpar streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Form 8-K Reneo Pharmaceuticals, For: Dec 14 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 Reneo.
Reneo stock plunges 84% as company shuts down lead program (NASDAQ:RPHM) seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.